Health Care [ 6/12 ] | Biotechnology [ 45/74 ]
NASDAQ | Common Stock
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.
In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia.
BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.21 Increased by +88.52% | -0.71 Increased by +70.42% |
| May 9, 24 | -0.87 Increased by +52.72% | -0.70 Decreased by -24.29% |
| Mar 12, 24 | -0.76 Increased by +61.03% | -0.91 Increased by +16.48% |
| Nov 14, 23 | -1.72 Decreased by -15.44% | -1.30 Decreased by -32.31% |
| Aug 14, 23 | -1.83 Decreased by -35.56% | -1.75 Decreased by -4.57% |
| May 8, 23 | -1.84 Decreased by -64.29% | -1.62 Decreased by -13.58% |
| Mar 9, 23 | -1.95 Decreased by -109.68% | -1.45 Decreased by -34.48% |
| Nov 10, 22 | -1.49 Decreased by -55.21% | -1.35 Decreased by -10.37% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 1.10 M Increased by +141.58% | -8.30 M Increased by +84.49% | Decreased by -751.72% Increased by +93.58% |
| Mar 31, 24 | 582.00 K Increased by +182.52% | -26.79 M Increased by +47.50% | Decreased by -4.60 K% Increased by +81.42% |
| Dec 31, 23 | 376.00 K Increased by +57.98% | -22.26 M Increased by +61.68% | Decreased by -5.92 K% Increased by +75.75% |
| Sep 30, 23 | 341.00 K Increased by +148.91% | -50.49 M Decreased by -13.15% | Decreased by -14.81 K% Increased by +54.54% |
| Jun 30, 23 | 457.00 K Increased by +N/A% | -53.52 M Decreased by -37.04% | Decreased by -11.71 K% Decreased by N/A% |
| Mar 31, 23 | 206.00 K Increased by +N/A% | -51.03 M Decreased by -62.18% | Decreased by -24.77 K% Decreased by N/A% |
| Dec 31, 22 | 238.00 K Increased by +N/A% | -58.09 M Decreased by -122.33% | Decreased by -24.41 K% Decreased by N/A% |
| Sep 30, 22 | 137.00 K Increased by +820.76% | -44.62 M Decreased by -66.42% | Decreased by -32.57 K% Increased by +81.93% |